Zoll discusses GE/Cardiac Science deal
This article was originally published in The Gray Sheet
Executive Summary
While "GE has been in the defibrillation business a few times," Zoll Medical CEO Richard Packer says the firm "never really goes at it with full force" as "they see [defibrillation] as complimentary" to their business, rather than "necessary." The exec's comments, which came June 15 at a Thomas Weisel conference, responded to a question about whether Zoll expected to feel any impact from Cardiac Science's recently inked North American distribution agreement with GE Healthcare for the PowerHeart ECD defibrillator (1"The Gray Sheet" May 9, 2005, p. 25). Zoll manufacturers the LifeVest defibrillator...
You may also be interested in...
Cardiac Science To Challenge Philips As Sole Biphasic AED Player In Japan
Cardiac Science anticipates receiving approval from the Japanese Ministry of Health, Labour & Welfare for a biphasic automated external defibrillator by the end of Q2, the firm says
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.
Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune
The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.